A brand new insulin will soon be on pharmacy shelves in the United States if Danish pharmaceutical company Novo Nordisk has its way. The company has filed for approval from the Food and Drug Administration to sell insulin degludec, an original formulation that lasts an extra-long time.
Insulin degludec is injected only once a day. Once under the skin, the dose of insulin is absorbed slowly and consistently, allowing for better nighttime control, according to Novo. Most importantly, test subjects had a low rate of hypoglycemia on the drug.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health.
Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.